Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shandong Provincial Hospital Affiliated to Shandong First Medical Univ. FLT3 compound 6h: sourced facts only. name: "Notably, the preliminary kinase selectivity results showed 6h displayed selectivity for FLT3 kinase (IC50 = 58.6 nM) over other kinases screened, including the homologous c-KIT." [PMID:42571759]; target: "Notably, the preliminary kinase selectivity results showed 6h displayed selectivity for FLT3 kinase (IC50 = 58.6 nM) over other kinases screened, including the homologous c-KIT." [PMID:42571759]; developer: "Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250012, China." [PMID:42571759]; stage: "Furthermore, in a MOLM-13 xenograft model, 6h at the dosage of 30 mg/kg exhibited effective antitumor activity without notable body-weight loss and the major organ damage." [PMID:42571759]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shandong Provincial Hospital Affiliated to Shandong First Medical Univ. FLT3 compound 6h.